Disseminated Mycobacterium chelonae infection resulting in endocarditis

Clinical Infectious Diseases

Volumn 23, Issue 6, 1996, Pages 1322-1323

  Galil, Karin ^a   Thurer, Robert ^b   Glatter, Kathryn ^b   Barlam, Tamar ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIAL ENDOCARDITIS; CASE REPORT; CLINICAL FEATURE; DEBRIDEMENT; FEMALE; GRANULOMATOUS INFLAMMATION; HUMAN; MYCOBACTERIOSIS; MYCOBACTERIUM CHELONEI; PRIORITY JOURNAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRICUSPID VALVE;

EID: 0030459730     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.6.1322     Document Type: Article

References (10)

1. Kusunoki S, Ezaki T. Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov. Int J Syst Bacteriol 1992;42:240-5.
2. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5:657-79.
3. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166: 405-12.
4. Geraci JE, Anderson MW, Karlson AG. Endocarditis due to a rapidly growing chromogenic mycobacterium. Mayo Clin Proc 1968;43:124-33.
5. Singh M, Bofinger A, Cave G, Boyle P. Mycobacterium fortuitum endocarditis in a patient with chronic renal failure on hemodialysis. Pathology 1992;24:197-200.
6. Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ III. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180-4.
7. Swenson JA, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985;28:807-11.
8. Tebas P, Sultan F, Wallace RJ Jr, Fraser V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995;20:443-4.
9. Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152: 500-14.
10. Viscidi R, Geller A, Caplan W, Natsios GA, Gleckman RA. Prosthetic valve endocarditis caused by Mycobacterium chelonei: case report and literature review. Heart Lung 1982; 11:555-9.